Collateral sensitivity as a strategy against cancer multidrug resistance. - Wikidata - awgldk - TriplyDB

Collateral sensitivity as a strategy against cancer multidrug resistance.

Collateral sensitivity as a strategy against cancer multidrug resistance.

http://www.wikidata.org/entity/Q35946556

about

Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions Using a sequential regimen to eliminate bacteria at sublethal antibiotic dosages The Role of Efflux Pumps in Schistosoma mansoni Praziquantel Resistant Phenotype Molecular Mechanisms for Drug Hypersensitivity Induced by the Malaria Parasite's Chloroquine Resistance Transporter Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer.Multidrug evolutionary strategies to reverse antibiotic resistance.Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306 A combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporter siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo.Multidrug resistance-selective antiproliferative activity of Piper amide alkaloids and synthetic analogues Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.Prediction of resistance development against drug combinations by collateral responses to component drugs.Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from Ambrosia maritima Against Multidrug-Resistant Cancer Cells Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.Mechanisms and insights into drug resistance in cancer The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene.Knockdown of ZFR suppresses cell proliferation and invasion of human pancreatic cancer.Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines.Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant.Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors Cost, effectiveness and environmental relevance of multidrug transporters in sea urchin embryos.Cytotoxicity and Modes of Action of the Methanol Extracts of Six Cameroonian Medicinal Plants against Multidrug-Resistant Tumor Cells A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway.ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks.Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors.Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model.Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1).Mechanisms and therapeutic potential of inhibiting drug efflux transporters.Collateral sensitivity of antibiotic-resistant microbes.Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel.Standardized Extract from Caesalpinia spinosa is Cytotoxic Over Cancer Stem Cells and Enhance Anticancer Activity of Doxorubicin.

P2860

Q26741336-51802741-E89A-4431-BDA3-80D9307995E1 Q28084270-16D8B487-76E1-4176-B190-15DEDA967E7E Q28486174-6B721F44-5E7C-403C-A38D-D9A2CCAA5E36 Q28535342-44B89EAB-DB33-46A7-8308-00633FB1410F Q28545933-CD000E98-FB44-4257-AEB1-E8B4313E536A Q28550120-05C0BF44-15BE-408D-9527-DE616ED7C44F Q28552775-279F6535-D50A-4869-B507-B89D8BE60EBE Q33682922-158B0629-AC69-4361-BD76-4F64E6177909 Q33685170-EDCB7AFE-9E13-40E5-ABC3-D00FBD5BFCFA Q33871101-001B63BD-60B4-4498-83EA-EC87B55CFD7B Q33985320-3CDF1BF4-8ED8-41DA-B194-7E4A48D73B6C Q34065942-9F20A745-D390-4029-ABFF-E1D40CF17457 Q34467622-BDE09C15-C00B-4401-BCA1-168C50833F36 Q34951877-7C499D4E-3FE8-4843-BA40-75C881EFBDB7 Q35197426-86E4B3C8-1C6F-482D-8586-1B8774C100E1 Q35832271-909074FA-B373-47CB-A9FA-EEE9DD957E69 Q35854877-CC228FEA-E47D-4932-9EA0-9A752836485D Q35870211-91053112-2844-43A8-95B8-F5B84D19411E Q35909089-B2067A81-A99E-401D-85F3-6F9CC45C656B Q36260937-D3FE7667-0145-460C-B403-B64330E59DCC Q36544608-C93DCDD6-89F2-43D3-B910-18912209CEF8 Q36682301-A7009EA6-2D63-41F0-B4C1-D488700CCCC3 Q36812960-6878C2B8-2196-4FE0-AA3F-5D3EB4C8C6AE Q36899540-CA86DDBE-DE06-4BF4-A705-597BFF1BA37C Q37168584-7BEB5BED-AA84-4C95-A015-741439CC67B5 Q37190276-435ED849-2143-4038-A25F-696EE7E932E5 Q37190433-7F3C2154-6012-4A91-98C2-EFBB65CD07AA Q37200589-AB33D74B-E6D5-495A-832E-217EC543CBDD Q37224836-6A06A508-833D-46D5-A43B-2EB513882979 Q37229409-55B8CE13-58E5-4438-A56E-E53C213657F6 Q37285224-71A6EB72-DFB3-4DFF-8D36-27F736A7D09F Q37357080-1540FAA7-07FB-4C16-9877-6E7F4488551C Q37438008-9B1D89B7-D341-4E3B-B9F4-B1257A01A9E4 Q37482728-EB7CEFE4-8C05-4899-966A-9D74D5EE97A7 Q37636632-152D4490-428C-49E4-9E65-081BFA29F356 Q37696966-67C860B6-AAF0-43C0-A234-A57ECDCB83F9 Q38388828-C52CC3EC-6D3D-473A-BE9F-4BFA21BA4BCA Q38394500-BD6DA977-E51E-410F-9AE5-7804BA0B7F28 Q38665011-874EFC05-F245-47EC-BEDB-C9F539FED977 Q38730830-5F03C736-6681-402C-BB50-CF33A72D9116

P2860

Collateral sensitivity as a strategy against cancer multidrug resistance.

http://www.wikidata.org/entity/Q35946556

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Collateral sensitivity as a strategy against cancer multidrug resistance.

@ast

Collateral sensitivity as a strategy against cancer multidrug resistance.

@en

type

label

Collateral sensitivity as a strategy against cancer multidrug resistance.

@ast

Collateral sensitivity as a strategy against cancer multidrug resistance.

@en

prefLabel

Collateral sensitivity as a strategy against cancer multidrug resistance.

@ast

Collateral sensitivity as a strategy against cancer multidrug resistance.

@en

P1433

Q35946556-34AD682D-0FC6-496A-9B0B-E6CBF7E71B5B

P1476

Q35946556-7D83E488-8CF4-4A44-85AF-AAB9F185A9CE

P2093

Q35946556-6C21664F-5EBB-4F1A-88C6-FC6166D27B50

Q35946556-7986602F-7FDC-4DC5-936C-B690B27C48D7

Q35946556-DB361410-F115-46E9-9F30-9F23DC4777C7

Q35946556-E68D0567-8B5E-4E9D-9BFA-B58A4D73D750

Q35946556-F7D49DC2-458C-4346-BF53-31E8C0306A45

P2860

Q35946556-012C0B93-1C05-4174-9C7E-9698DFE85FF8

Q35946556-01DB0EC6-71D2-481E-B154-0D4E70177FAB

Q35946556-0285F223-D1B5-48EC-AD87-6E41932FC8F9

Q35946556-075408CA-8347-4A00-8D17-9F18FA8BE8C0

Q35946556-0CA078AC-84B8-41ED-A719-09BBF1FDF1BF

Q35946556-0D1F8E32-7496-43BC-8C01-6542A2FCA48C

Q35946556-0F0DFD37-2717-4CC8-BAF6-130E79A39F5E

Q35946556-1028D7CB-3232-46FF-A948-37BE30454C5B

Q35946556-15B50AB5-01E6-4DE2-87FA-086844AAA100

Q35946556-1C6E2C05-3F59-4295-B921-ABFFFCE4D45C

P304

Q35946556-F68ECF3C-054A-488D-8072-4271B1EE76D8

P31

Q35946556-6D30A1F6-86B0-4EEF-BE8B-D9F836ADA284

P356

Q35946556-83EC1600-1957-45B1-8716-9D92DD130D5E

P433

Q35946556-F476C2BF-F06F-47A1-A17A-A489E001662E

P478

Q35946556-949F71E7-D71B-48E4-8248-214A8C85F6A7

P577

Q35946556-D8C0E247-D536-41B6-BBFD-1DA4DF482D1C

P5875

Q35946556-B9E3528C-53DA-4D8C-B393-3227714C4330

P698

Q35946556-B774EE9B-AC10-4FCA-BF01-6BA291A12F0A

P921

Q35946556-AAF8C861-EAC9-4AFF-829D-A2EB38BA2704

P932

Q35946556-3C384526-4673-4681-BC8F-59B7A9F2D3C8

P356

J.DRUP.2012.03.002

P1433

Drug Resistance Updates

P1476

Collateral sensitivity as a strategy against cancer multidrug resistance.

@en

P2093

Andrew S Goldsborough

http://www.w3.org/2001/XMLSchema#string

Kristen M Pluchino

http://www.w3.org/2001/XMLSchema#string

Matthew D Hall

http://www.w3.org/2001/XMLSchema#string

Michael M Gottesman

http://www.w3.org/2001/XMLSchema#string

Richard Callaghan

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Multidrug resistance in cancer: role of ATP-dependent transporters

Regulation of cancer cell metabolism

Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate

Targeting multidrug resistance in cancer

Otto Warburg's contributions to current concepts of cancer metabolism

Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

Treatment of cystinuria.

Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues

P304

98-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUP.2012.03.002

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223965211

http://www.w3.org/2001/XMLSchema#string

P698

22483810

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

3348266

http://www.w3.org/2001/XMLSchema#string